These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22322589)

  • 21. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
    Miyamae T; Yokoya S; Yamanaka H; Yokota S
    Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH; Xavier RM
    Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab.
    Tsuru T; Terao K; Murakami M; Matsutani T; Suzaki M; Amamoto T; Nakashima H; Akiyama A; Nishimoto N
    Mod Rheumatol; 2014 May; 24(3):511-6. PubMed ID: 24252023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
    Pardeo M; Wang J; Ruperto N; Alexeeva E; Chasnyk V; Schneider R; Horneff G; Huppertz HI; Minden K; Onel K; Zemel L; Martin A; Koné-Paut I; Siamopoulou-Mavridou A; Silva CA; Porter-Brown B; Bharucha KN; Brunner HI; De Benedetti F;
    J Rheumatol; 2019 Sep; 46(9):1117-1126. PubMed ID: 30824645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fulminant bilateral papilloedema during low-dose steroid taper in a child with systemic idiopathic arthritis treated with tocilizumab.
    Burstzyn L; Levin S; Rotenberg B; Van Hooren T; Leung A; Berard R; Ardelean DS
    Clin Exp Rheumatol; 2017; 35(1):149-151. PubMed ID: 27974106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
    Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
    Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
    Frampton JE
    Paediatr Drugs; 2013 Dec; 15(6):515-31. PubMed ID: 24155139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza vaccine uptake in juvenile idiopathic arthritis: a multi-centre cross-sectional study.
    Maritsi D; Dasoula F; Ziv A; Bizjak M; Balažiová B; Matošević M; Yildiz M; Alpert N; Lamot L; Kasapcopur O; Dallos T; Uziel Y; Toplak N; Heshin-Bekenstein M
    Eur J Pediatr; 2024 Jul; 183(7):2937-2944. PubMed ID: 38619568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 32. Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment.
    Kostik MM; Isupova EA; Chikova IA; Dubko MF; Masalova VV; Snegireva LS; Kalashnikova OV; Chasnyk VG
    Clin Exp Rheumatol; 2018; 36(2):335-341. PubMed ID: 29303703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.
    Aikawa NE; Campos LM; Goldenstein-Schainberg C; Saad CG; Ribeiro AC; Bueno C; Precioso AR; Timenetsky Mdo C; Silva CA; Bonfá E
    Scand J Rheumatol; 2013; 42(1):34-40. PubMed ID: 22992045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
    Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E
    Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
    Sukharomana M; Udomittipong K; Ruangchira-Urai R; Charuvanij S
    Asian Pac J Allergy Immunol; 2022 Jun; 40(2):172-176. PubMed ID: 31837211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.
    Woo P; Wilkinson N; Prieur AM; Southwood T; Leone V; Livermore P; Wythe H; Thomson D; Kishimoto T
    Arthritis Res Ther; 2005; 7(6):R1281-8. PubMed ID: 16277681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Herlin T
    Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
    Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
    Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
    Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics.
    Pal P; Giri PP; Sinha R
    Indian J Pediatr; 2019 Jul; 86(7):590-594. PubMed ID: 30937723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.